Compare GAME & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | ATYR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 51.7M |
| IPO Year | 2024 | N/A |
| Metric | GAME | ATYR |
|---|---|---|
| Price | $0.36 | $0.51 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 604.5K | ★ 938.9K |
| Earning Date | 04-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $87.12 | N/A |
| Revenue Next Year | $21.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.40 |
| 52 Week High | $1.09 | $6.50 |
| Indicator | GAME | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 47.47 |
| Support Level | $0.26 | $0.46 |
| Resistance Level | $0.47 | $0.86 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 24.70 | 58.49 |
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).